Should I buy or sell Dr. Reddy's Laboratories stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares. View RDY analyst ratings or view top-rated stocks .

What is Dr. Reddy's Laboratories' stock price target for 2024?

4 equities research analysts have issued 12-month price objectives for Dr. Reddy's Laboratories' stock. Their RDY share price targets range from $70.00 to $70.00. On average, they anticipate the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View analysts price targets for RDY or view top-rated stocks among Wall Street analysts .

How have RDY shares performed in 2023?

Dr. Reddy's Laboratories' stock was trading at $51.75 on January 1st, 2023. Since then, RDY shares have increased by 34.9% and is now trading at $69.83. View the best growth stocks for 2023 here .

Are investors shorting Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,060,000 shares, a drop of 16.5% from the October 31st total of 1,270,000 shares. Based on an average trading volume of 248,000 shares, the short-interest ratio is currently 4.3 days. View Dr. Reddy's Laboratories' Short Interest .

When is Dr. Reddy's Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 24th 2024. View our RDY earnings forecast .

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) issued its quarterly earnings results on Friday, October, 27th. The company reported $1.07 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.19. The company earned $832.16 million during the quarter, compared to analyst estimates of $825.94 million. Dr. Reddy's Laboratories had a net margin of 19.09% and a trailing twelve-month return on equity of 21.47%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Tuesday, July 18th. Investors of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a dividend yield of 0.7%. The ex-dividend date is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33. Read our dividend analysis for RDY .

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.59%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 11.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 10.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RDY .

What ETFs hold Dr. Reddy's Laboratories' stock?

ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include ALPS Emerging Sector Dividend Dogs ETF (EDOG) , First Trust BICK Index Fund (BICK) , Putnam Panagora ESG Emerging Markets Equity ETF (PPEM) , Inspire Tactical Balanced ETF (RISN) , Inspire Fidelis Multi Factor ETF (FDLS) , Hartford Multifactor Emerging Markets ETF (ROAM) and Invesco S&P Emerging Markets Low Volatility ETF (EELV) . SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG) .

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com . G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY) , Tata Motors (TTM) , Infosys (INFY) , HDFC Bank (HDB) , Alibaba Group (BABA) , GSK (GSK) , Merck & Co., Inc. (MRK) , NVIDIA (NVDA) and Pfizer (PFE) .

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Royal Bank of Canada (1.29%), Robeco Institutional Asset Management B.V. (1.00%), Morgan Stanley (0.44%), Ameriprise Financial Inc. (0.26%), Acadian Asset Management LLC (0.16%) and Grantham Mayo Van Otterloo & Co. LLC (0.15%).

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Dr. Reddy's Laboratories Stock Price, News & Analysis (NYSE:RDY)

$69.83

+0.25 (+0.36%)

(As of 12/4/2023 ET)

Compare

Today's Range: $69.47
▼
$70.01
50-Day Range: $64.27
▼
$69.90
52-Week Range: $51.11
▼
$73.17

Volume: 349,987 shs
Average Volume: 241,640 shs
Market Capitalization: $11.65 billion

P/E Ratio: 18.82
Dividend Yield: 0.59%
Price Target: $70.00

Dr. Reddy's Laboratories MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.2% Upside
$70.00 Price Target
Short Interest: Healthy
0.64% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.78
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 5.96%
From $3.86 to $4.09 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

827th out of 951 stocks

Drug Manufacturers - Specialty & Generic Industry

2nd out of 2 stocks

1.0

Analyst's Opinion

Consensus Rating
Dr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $70.00, Dr. Reddy's Laboratories has a forecasted upside of 0.2% from its current price of $69.83.
Amount of Analyst Coverage
Dr. Reddy's Laboratories has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.64% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.
Short Interest Ratio / Days to Cover
Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Dr. Reddy's Laboratories has recently decreased by 16.54%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Dr. Reddy's Laboratories has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dr. Reddy's Laboratories has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of Dr. Reddy's Laboratories is 11.05%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.02% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RDY.

2.7

News and Social Media Coverage

News Sentiment
Dr. Reddy's Laboratories has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for RDY on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.
Percentage Held by Institutions
Only 12.42% of the stock of Dr. Reddy's Laboratories is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Dr. Reddy's Laboratories are expected to grow by 5.96% in the coming year, from $3.86 to $4.09 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dr. Reddy's Laboratories is 18.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.56.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dr. Reddy's Laboratories is 18.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.92.
Price to Earnings Growth Ratio
Dr. Reddy's Laboratories has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Dr. Reddy's Laboratories has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dr. Reddy's Laboratories Stock (NYSE:RDY)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RDY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RDY Stock News Headlines

November 20, 2023 | marketbeat.com

2 overlooked stocks that crushed earnings but traded lower (RDY)

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

December 2, 2023 | americanbankingnews.com

FY2025 Earnings Estimate for Dr. Reddy's Laboratories Limited Issued By Zacks Research (NYSE:RDY)

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 30, 2023 | americanbankingnews.com

Q4 2025 Earnings Estimate for Dr. Reddy's Laboratories Limited Issued By Zacks Research (NYSE:RDY)

November 20, 2023 | msn.com

Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term

October 30, 2023 | finance.yahoo.com

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

October 27, 2023 | msn.com

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

October 27, 2023 | finance.yahoo.com

Dr. Reddy’s Q2 FY24 Financial Results

December 4, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

October 26, 2023 | finance.yahoo.com

All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy

October 11, 2023 | finance.yahoo.com

Here's Why Doctor Reddy's (RDY) is a Strong Growth Stock

October 4, 2023 | finance.yahoo.com

3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)

September 29, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals

September 26, 2023 | finance.yahoo.com

Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

September 25, 2023 | finance.yahoo.com

Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term

September 18, 2023 | finance.yahoo.com

Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

September 13, 2023 | finance.yahoo.com

Zacks.com featured highlights Caterpillar, KB Home, Walmart, Dr. Reddy's Laboratories and FedEx

September 8, 2023 | msn.com

These 3 Low-Beta Stocks Sport High Growth

August 31, 2023 | finance.yahoo.com

Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

August 18, 2023 | msn.com

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

August 14, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

August 10, 2023 | msn.com

Dr. Reddy's launches generic version of Kombiglyze XR in US

August 10, 2023 | seekingalpha.com

Dr. Reddy's Laboratories Limited 2024 Q1 - Results - Earnings Call Presentation

July 28, 2023 | msn.com

Chart of the Day: What's Cooking at Dr. Reddy's Lab

July 28, 2023 | finance.yahoo.com

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

July 27, 2023 | finance.yahoo.com

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q1 2024 Earnings Call Transcript

July 27, 2023 | chron.com

Doctor Reddy's: Fiscal Q1 Earnings Snapshot

See More Headlines

Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/27/2023
Today: 12/04/2023
Next Earnings (Estimated): 1/24/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:RDY
CUSIP: N/A
CIK: 1135951
Web: www.drreddys.com
Phone: 914049002900
Fax: 91-40-4900-2999
Employees: 25,863
Year Founded: 1984

Price Target and Rating

Average Stock Price Target: $70.00
High Stock Price Target: $70.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +0.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.71
Trailing P/E Ratio: 18.82
Forward P/E Ratio: 18.09
P/E Growth: 2.06
Net Income: $548 million
Net Margins: 19.09%
Pretax Margin: 24.81%
Return on Equity: 21.47%
Return on Assets: 15.52%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 2.59
Quick Ratio: 1.91

Sales & Book Value

Annual Sales: $2.99 billion
Price / Sales: 3.89
Cash Flow: $4.23 per share
Price / Cash Flow: 16.51
Book Value: $16.87 per share
Price / Book: 4.14

Miscellaneous

Outstanding Shares: 166,860,000
Free Float: 163,520,000
Market Cap: $11.65 billion
Optionable: Optionable
Beta: 0.55

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Gunupati Venkateswara Prasad B.E. (Age 63)
Co-Chairman, MD & Member of Management Council
Comp: $2.25M
Mr. Kallam Satish Reddy B.Tech. (Age 56)
M.S., Chairman of the Board & Member of the Management Council
Comp: $1.38M
Mr. Erez Israeli M.B.A. (Age 55)
CEO & Member of the Management Council
Mr. Parag Agarwal (Age 56)
CFO & Member of Management Council
Mr. Deepak Sapra M.B.A. (Age 48)
CEO of API & Services & Member of Management Council
Mr. Venkata Ramana Motupalli M.B.A. (Age 54)
CEO of Branded Markets - India & Emerging Countries and Member of Management Council
Ms. Archana Bhaskar B.Sc. (Age 56)
M.B.A., EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Mr. Sanjay Sharma B.Tech. (Age 55)
Executive VP, Global Head of Global Manufacturing & Member of Management Council
Mr. Marc Kikuchi B.A. (Age 54)
M.B.A., CEO of North America Generics & Member of Management Council
Mr. Patrick Aghanian B.A. (Age 58)
M.B.A., CEO of European Generics & Member of Management Council

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RDY Stock Analysis - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.
View RDY analyst ratings or view top-rated stocks.
What is Dr. Reddy's Laboratories' stock price target for 2024?: 4 equities research analysts have issued 12-month price objectives for Dr. Reddy's Laboratories' stock. Their RDY share price targets range from $70.00 to $70.00. On average, they anticipate the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 0.2% from the stock's current price.
View analysts price targets for RDY or view top-rated stocks among Wall Street analysts.
How have RDY shares performed in 2023?: Dr. Reddy's Laboratories' stock was trading at $51.75 on January 1st, 2023. Since then, RDY shares have increased by 34.9% and is now trading at $69.83.
View the best growth stocks for 2023 here.
Are investors shorting Dr. Reddy's Laboratories?: Dr. Reddy's Laboratories saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,060,000 shares, a drop of 16.5% from the October 31st total of 1,270,000 shares. Based on an average trading volume of 248,000 shares, the short-interest ratio is currently 4.3 days.
View Dr. Reddy's Laboratories' Short Interest.
When is Dr. Reddy's Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 24th 2024.
View our RDY earnings forecast.
How were Dr. Reddy's Laboratories' earnings last quarter?: Dr. Reddy's Laboratories Limited (NYSE:RDY) issued its quarterly earnings results on Friday, October, 27th. The company reported $1.07 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.19. The company earned $832.16 million during the quarter, compared to analyst estimates of $825.94 million. Dr. Reddy's Laboratories had a net margin of 19.09% and a trailing twelve-month return on equity of 21.47%.
How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?: Dr. Reddy's Laboratories announced an annual dividend on Tuesday, July 18th. Investors of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a dividend yield of 0.7%. The ex-dividend date is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33.
Read our dividend analysis for RDY.

Is Dr. Reddy's Laboratories a good dividend stock?: Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.59%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 11.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 10.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.
What ETFs hold Dr. Reddy's Laboratories' stock?: ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include ALPS Emerging Sector Dividend Dogs ETF (EDOG), First Trust BICK Index Fund (BICK), Putnam Panagora ESG Emerging Markets Equity ETF (PPEM), Inspire Tactical Balanced ETF (RISN), Inspire Fidelis Multi Factor ETF (FDLS), Hartford Multifactor Emerging Markets ETF (ROAM) and Invesco S&P Emerging Markets Low Volatility ETF (EELV).SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG).
What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?: 528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Dr. Reddy's Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).
Who are Dr. Reddy's Laboratories' major shareholders?: Dr. Reddy's Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Royal Bank of Canada (1.29%), Robeco Institutional Asset Management B.V. (1.00%), Morgan Stanley (0.44%), Ameriprise Financial Inc. (0.26%), Acadian Asset Management LLC (0.16%) and Grantham Mayo Van Otterloo & Co. LLC (0.15%).
How do I buy shares of Dr. Reddy's Laboratories?: Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:RDY) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial